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ABSTRACT

	
  

Endophytes are bacterial and fungal microbes that live inside of plant tissue without
causing disease. Endophytes have applications in many industries including the pharmaceutical
and food industries as producers of natural products. This potential was demonstrated by
investigating the natural product production from a Bacillus amyloliquefaciens endophyte of
Platanus occidentalis using a combination of MALDI-IMS, LC-MS, MS-MS, and NMR
methods, by purifying nicotianamine from soy flour, and by reviewing natural product inhibitors
of the hepatitis C virus (HCV).
The secondary metabolite production of the endophytic B. amyloliquefaciens was
investigated under a variety of fermentation conditions. It was discovered that the endophyte
produces rapamycin, a molecule previously reported only from Streptomyces hygroscopicus
from Easter Island in the South Pacific. Other known natural products from the Bacillus genus
were identified using LC-MS including the lipopeptide fengycins, surfactins, and iturins. Iturin
A3 was isolated and characterized from the endophyte, and found in the host P. occidentalis, as
shown by LC-MS. The presence of a possible rapamycin analogue was discovered which would
be indicative of a biotransformation process. Challenge experiments were conducted using
MALDI-IMS in an attempt to understand host regulation of secondary metabolites. Iturin
production increased as shown by MALDI-IMS.
The impetus for studying endophytes like B. amyloliquefaciens for natural products was
further exemplified by purifying a natural metal chelator, nicotianamine, from soy flour. This is
a possible candidate to replace ethylenediaminetetraacetic acid (EDTA), a synthetic metal

	
  

ii	
  

chelator used to prevent food spoilage. Further studies on possible endophytic production of
nicotianamine could be of great importance to many food companies. The importance of
studying endophytes was further shown by reviewing the number of novel and known natural
products that have been reported with activity against the hepatitis C virus (HCV). There are
numerous examples in the literature of metabolites being reported as plant-derived which are
later identified as ultimately being produced by endophytic organisms. This review
demonstrates the importance of studying new and known sources of HCV active metabolites for
endophytic organisms.
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CHAPTER ONE: INTRODUCTION
Endophytes are bacterial and fungal microbes that live inside of plant tissue without causing

disease. Endophytes have applications in many industries including the pharmaceutical and food
industries as producers of natural products. This potential was demonstrated by investigating
the natural product production from a Bacillus amyloliquefaciens endophyte of Platanus
occidentalis using a combination of MALDI-IMS, LC-MS, MS-MS, and NMR methods, by
studying the production of nicotianamine from soy flour, and by reviewing natural product
inhibitors of the hepatitis C virus (HCV).
The secondary metabolite production of the endophytic Bacillus amyloliquefaciens was
investigated under a variety of fermentation conditions. It was discovered that the B.
amyloliquefaciens produces rapamycin, a molecule previously reported only from Streptomyces
hygroscopicus from Easter Island in the South Pacific. Other known natural products from
Bacillus sp. were identified using LC-MS including the antifungal lipopeptide fengycins,
surfactins, and iturins. Iturin A3 was isolated and characterized from the endophytic B.
amyloliquefaciens, and found in the host P. occidentalis, as shown by LC-MS. The presence of
a possible rapamycin analogue was discovered which would be indicative of a biotransformation
process. Challenge experiments were conducted using MALDI-IMS in an attempt to understand
host regulation of secondary metabolites. Iturin production increased as shown by MALDI-IMS.
The impetus for studying endophytes like B. amyloliquefaciens for natural products was
further exemplified by purifying a natural metal chelator, nicotianamine, from soy flour. This is
a possible candidate to replace ethylenediaminetetraacetic acid (EDTA), which is a synthetic
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metal chelator that is used to prevent food spoilage. Further studies on possible endophytic
production of nicotianamine could be of great importance to many food companies. The
importance of endophytes was further demonstrated by reviewing natural product hepatitis C
virus (HCV) inhibitors. There are numerous examples in the literature of metabolites being
reported as plant-derived which are later identified as ultimately being produced by endophytic
organisms. This review demonstrates the importance of studying new and known sources of
HCV active metabolites for endophytic organisms.
Platanus occidentalis and Bacillus amyloliquefaciens
Platanus occidentalis (American Sycamore) is an Eudicotyledon species of tree that has a
native range that primarily exists east of the Great Plains region in the United States but also
extends into parts of southern Ontario and the mountainous region of northeastern Mexico
(Figure 1).1 Fully mature trees are characterized by exfoliating bark that leaves portions of inner
bark exposed and leads to a patchwork appearance with different areas of grey, brown, white,
and green. Trees are deciduous and leaves are palmate-veined with three to five lobes per leaf
and are among the largest trees in Eastern deciduous forests. American Sycamore is a fastgrowing species often grown in plantations for pulp or dimensional lumber products.1 It has been
used in the rehabilitation of saturated soils and strip-mined land and is an early colonizer of
waterway disposal sites and degraded stream banks. Ethnobotanic uses by Native Americans
include the treatment of colds, respiratory ailments, as gastrointestinal and gynecological aids,
and for uses in dermatological problems.1 Previously, one known and three novel glycosides
were isolated from P. occidentalis leaf tissue that showed significant activity against MRSA
(Figure 2).2 In order to more fully understand the pharmacological potential of this native tree,
the secondary metabolite production of an endophyte that is involved in a mutualism with P.
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occidentalis was studied.
Mutualism is an association between two organisms that benefits both organisms. These
types of associations abound in nature and certain mutualistic relationships play important roles
in plant health. For example, mycorrhizal fungi form symbiotic relationships with plant roots
whereby plants gain increased surface area for mineral and water absorption from the soil while
the fungal symbionts derive nutrition from plant-produced carbohydrates. Plants contributing in
this symbiosis are more resistant to drought and disease.3-4 Plants benefit in a number of other
ways through this association, many of which are still being researched. It is currently estimated
that 80% of plant species and 92% of plant families

Figure 1 Platanus occidentalis species with leaf inset

	
  

have mycorrhizal associations with fungi.5 Another important mutualism exists between plants
and nitrogen-fixing bacteria whereby bacteria dwelling inside the root nodules of certain plant

	
  

3	
  

species fix nitrogen and make it available to the host plant and, after the host dies, to the soil.
Yet another important mutualism exists between bacterial and/or fungal microbes and their plant
hosts.
Endophytes are bacteria and/or fungi that reside in living plant tissue without causing
disease. There are examples of bacterial and fungal species that can exist as both endophytes
and pathogens depending on many factors including different stages of the microorganism’s life
cycle or environmental conditions. Thus, the nature of the host-microbe association must be
taken into account when labeling a microorganism as an endophyte.6 Although estimates vary, it
is currently accepted that there are over 300,000 higher plants on Earth, and each species that has
been examined for endophytes
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Figure 2 MRSA active glycosides isolated from P. occidentalis leaf tissue
has contained them. One of the best studied endophyte and plant host mutualisms occurs
between fungal endophytes and various grasses. It has been shown in native grasses that the
presence of fungal endophytes decreases herbivory.7 These fungal endophytes produce
insecticidal alkaloids that have proven activity against both vertebrates and insect pests.8 The
ecology of endophytes and how they contribute to plant health is an active and compelling area
of research. One of the recognized functions of endophytes is to provide natural products to the
host plant that aid in protection and survival. Many of these compounds have human uses in
agriculture, industry, and in medicine as antibiotics, antimycotics, immunosuppressants, and as
chemotherapeutic compounds.9 One of the endophytes that was isolated from P. occidentalis was
identified by colony morphology, and later by 16S rRNA analysis, as B. amyloliquefaciens.

	
  
Figure 3 Transmission electron microscopy image of Bacillus subtilis. Endospore is shown.
(Photo courtesy of NCI at Frederick: http://ncifrederick.cancer.gov/atp/cms/wpcontent/uploads/2010/11/bacteria_021.jpg)
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Bacillus spp. are rod-shaped, motile, and aerobic. They can produce endospores to
survive unfavorable conditions and, until the advent of molecular phylogenetics, this was the
defining characteristic that placed a bacterium within the genus.10 B. subtilis is used as a model
organism for Gram-positive bacteria and is one of the most well known and studied Grampositive species (Figure 3). The fact that B. subtilis and other Bacillus species can form such
hardy spores, and that these spores are often dispersed by wind, has made characterizing the
preferred environment of B. subtilis difficult.11 However, there is mounting evidence that the
environments where B. subtilis can survive are extremely diverse. These include soil, plant
roots, and within the GI tract of animals.11 Soil dwelling B. subtilis species have been shown to
be involved in plant growth promotion.12 The presence of B. subtilis spores in the GI tract of
many animals including humans has been known for many years, and this was assumed to be due
to the ingestion of food contaminated by spores. However, there is growing evidence that B.
subtilis are actually involved in a mutualistic relationship with the host animal species.13
The full genome of B. subtilis was published in1997.14 The genome was reported to contain
4,214,810 base pairs which correlated with 4,100 protein coding genes. Interestingly, a number
of these genes are devoted to the production of proteins involved in the utilization of plantderived molecules.14
Some other commonly known Bacillus species are B. anthracis, B. thuringiensis, and B.
cereus. B. anthracis causes anthrax by producing the anthrax toxin that has been developed into
a biological weapon by a number of countries. B. thuringiensis produces pesticidal crystal
proteins and is the most widely used biorational pesticide.15 Certain B. cereus strains are
responsible for a number of food poisoning cases.
The genome of B. amyloliquefaciens FZB42 strain was comparatively analyzed in
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2007.16 The particular B. amyloliquefaciens strain that was analyzed, B. amyloliquefaciens
FZB42, has been reported as a rhizobacterium. It was reported that more than 8.5% of the
genome was devoted to synthesizing siderophores and antibiotics using non-ribosomal
pathways.16 A number of genes that were previously identified as being involved in bacteriumplant interactions were also identified. These include genes involved in: the production of an
exopolysaccharide that holds bacterial cells together; the production of surfactin for the
colonization of plant surfaces; and the production of extra-cellular macromolecular
depolymerases for growing on plant surfaces.16 A number of PKS and NRPS genes were also
identified, although the putative synthetic secondary metabolites are unknown.16
The secondary metabolite production of Bacillus spp. was reviewed comprehensively by
Sansinenea and Ortiz in 2011.17 Bacillus spp. produce a diverse array of natural products
including bacteriocins, lantibiotics, lipopeptides, and polyketides.17 Bacteriocins are peptides or
proteins that can vary in structure and molecular weight and typically are active against bacteria
that are closely related to the producer organism. A B. licheniformis strain which was isolated
from buffalo rumen produces lichenin, a bacteriocin with a mass of approximately 1400 daltons
and length of 12 amino acids.18 A bacteriocin peptide of 44 residues called coagulin, produced
by B. coagulans, has proven antilisterial activity.19 Polyfermenticin SCD is another bacteriocin
produced by B. polyfermenticus that has shown narrow spectrum activity against certain bacteria
as well as yeasts and molds and has a mass of approximately 14.3 kilodaltons.20
Lantibiotics are a group of polycyclic compounds that are formed by the posttranslational
modification of serine and threonine residues. These residues are dehydrated and then the thiol
group of cysteine residues are added in intramolecular reactions to form lanthionine and
methyllantionine bridges.21 B. subtilis produces many lantibiotics including subtilin, ericin, and
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mersacidin, among others.22 Subtilin is by far the most widely studied of this group of secondary
metabolites. It is composed of 32 amino acids and has activity against mostly Gram-positive
species as well as many pathogenic fungi.23 Another group of secondary metabolites that has
been isolated from Bacillus species are the lipopeptides (Figure 4).17 Lipopeptides consist of a
short fatty acid chain linked to a linear or cyclized peptide.24 Certain lipopeptides have exhibited
antimicrobial, immunosuppressant, and cytotoxic activity.24-26

Figure 4 Representative examples of the famlies of lipopeptides produced by Bacillus spp. (A)
surfactins, (B) iturins, and (C) fengycins.
The three groups of lipopeptides produced by Bacillus spp. are the surfactins, iturins, and
fengycins. These groups are defined by the number of amino acids within the cyclized peptide
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moiety. Variants within groups are established by having different amino acid residues at
different positions or differences in the lipid tail.24 Most of these molecules also have
demonstrated surfactant properties and the most widely studied lipopeptides are the surfactin
group.27 The surfactin group contains molecules with a heptapeptide moiety linked to a βhydroxy fatty acid chain.24 Surfactin 5 has demonstrated biosurfacant properties, as well as
antiviral and antimycoplasma activity.28 The iturins contain seven cyclized amino acids and a βamino fatty acid. They are differentiated by variations of amino acids at different positions and
also by variation in the branching or length of the β- amino fatty acid.29 Iturins have
demonstrated activity against fungal plant pathogens including Podosphaera fusca,29 Rhizoctonia
solani,30 and a number of iturin-producing Bacillus species are currently in use as bio-control
agents for many other fungal pathogens.31 The fengycin group of lipopeptides contain 10 amino
acids, eight of which form a lactone via a linkage between tyrosine and isoleucine. The βhydroxy fatty acid is linked to the peptide moiety through an amide bond with the α-amino group
of glutamic acid.24 Members of this group of lipopeptides have shown selective activity against
filamentous fungi and certain agricultural pests.32
Polyketides are another group of secondary metabolites that have been isolated from B.
subtilis (Figure 5). Difficidin and oxydifficidin are two macrocyclic polyene lactone phosphate
esters that were first isolated and characterized in 1987 from B. subtilis.33 Difficidin has also
been isolated from the plant-associated B. amyloliquefaciens and has proven activity against fire
blight in orchard trees caused by Erwinia amylovora.34-35 Bacillaene is another polyketide that
was reported from B. subtilis in 1995 and has also recently shown activity against E.
amylovora.34 The production of bacillaene was discovered to be through an approximately 80 kb
pksX gene cluster that encodes an uncommon polyketide/nonribosomal peptide synthase.36
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Multiple copies of this synthase form a megacomplex with an expected mass of tens to hundreds
of megadaltons to produce bacillaene, which contains two amide bonds and is not cyclized.36
Macrolactins are a group of compounds which contain three separated diene components within
a 24-membered lactone. The first macrolactin was isolated from an unidentified deep sea
bacterium.37 Macrolactin F was later isolated from an identified marine Bacillus sp. and

	
  
Figure 5 Representative examples of polyketides produced by Bacillus spp. (A) difficidin and
oxydifficidin, (B) macrolactin F, and (C) bacillaene (stereochemistry unknown).
macrolactin S has also been isolated from a Bacillus spp. Macrolactin S showed unique activity
against the Staph. aureus FabG protein, and 7-O-malonylmacrolactin A, which showed activity
against MRSA and vanomycin-resistant enterococci.38-39
One of the most important polyketides from a drug discovery standpoint is rapamycin
(Figure 6). Rapamycin was first isolated from the actinomycete Streptomyces hygroscopicus,
which was isolated from a soil sample collected on Easter Island in the southeastern Pacific
Ocean in 1975.40-41 It was first reported as an antifungal product; subsequent studies
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demonstrated rapamycin possessed significant activity against mammalian brain tumors42 and
immune cells.43 Investigations into the mechanism of action of rapamycin led to the discovery of
TOR 1-1 (Target of Rapamycin) and TOR2-1 genes in Saccharomyces cerevisiae.44 These genes
are conserved in all eukaryotes, excepting metazoans which only contain one TOR gene, and are
now known to code for serine/threonine protein kinases that are part of larger multiprotein
complexes called TORC (TOR Complex) 1 and TORC 2.45-48 These

Figure 6 Rapamycin structure

	
  

kinases are master regulators of eukaryotic cells, responsible for coordinating environmental
signals with cell growth.45
For many years, it was believed that plants were resistant to rapamycin. However, it was
shown that rapamycin inhibits root and leaf growth.49 Seedling and cellular assays were used to
monitor TOR kinase activity by measuring S6 kinase (S6K) phosphorylation, and showed that, in
plants, rapamycin inhibited the phosphorylation of Thr-449 and Thr-455 of S6K1 and S6K2,
respectively. It had previously been shown that growth of Arabidopsis seedlings after
germination strictly relies on glucose for growth.50 Using this newly developed assay, it was
shown that glucose strongly activates TOR PK activity. Subsequently, it was shown that the
presence of rapamycin had a detrimental effect on seedling growth by interfering with glucoseTOR signaling. Seedlings grown in the presence of rapamycin had underdeveloped cotyledons,
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leaves, petioles, and primary and lateral roots, leading to the conclusion that reports of plant
resistance to rapamycin were false.49 A more recent paper further illustrated the importance of
glucose-TOR signaling for plant development and growth.51 This study concentrated on the the
photoautotrophic transition checkpoint, when a seedling transitions from acting as a heterotroph,
relying on seed material, to a photoautotroph, synthesizing carbohydrates through
photosynthesis. It was discovered that glucose-TOR signaling has a direct relationship to root
meristem stem/progenitor cell proliferation and overall plant growth through inter-organ
coordination.51 The presence or absence of rapamycin was not linked to fluctuations in levels of
auxins, or cytokines, or the the maintenance of the stem cell niche, but was instead specifically
linked to changes in the cell cycle of the root meristem. They discovered 1,318 up regulated and
1,050 down regulated genes related to TOR-glucose signaling. Interestingly, tor mutant plants
did not undergo any of these transcriptome changes once again demonstrating the importance of
TOR PK to plant development.51
Rapamycin has recently proved to have some anti-aging properties in mice models.52
Current data suggest that the prevention of cancer is responsible for life extension in mice as
opposed to acting on aging itself. Rapamycin and rapamycin analogues are approved for the
treatment of many different types of diseases. Rapamycin is currently approved for use in
kidney transplantation and has a mechanism of action that is unique from that of other
immunosuppressants including tacrolimus and cyclosporin.53 These two agents act by inhibiting
the transcription of calcineurin phosphatase, thus preventing the transcription of cytokines.
Rapamycin exerts its effects through binding to mTOR and has the ability to synergize with
other immunosuppressants.53 The rapamycin analog everolimus is approved for the treatment of
subependymal giant cell astrocytoma (SEGA), advanced hormone receptor-positive, HER2-
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negative breast cancer, progressive neuroendocrine tumors of pancreatic origin, and advanced
renal cell carcinoma.54 Temsirolimus is another derivative which was developed to decrease
immunosuppressive properties and increase solubility and is approved for advanced renal cell
carcinoma.55
Imaging mass spectrometry (IMS) is a technology that is currently finding widespread
use in drug discovery for the study of biomarkers56 and more recently the metabolism and tissue
distribution of therapeutic agents.57 IMS has also emerged in the relatively recent past as a new
tool in natural products research. The use of IMS involves three basic steps, which can vary
considerably depending on which ionization technique is involved. For the work presented here,
all IMS data were acquired using MALDI-IMS. In MALDI-IMS, the workflow can be divided
into four steps: sample preparation, matrix application, measurement, and data analysis.58 A
variety of techniques including MALDI-IMS, NMR, and LC-MS can be used to study endophyte
produced metabolites.
Nicotianamine
Nicotianamine (NA) is found in all higher plants where it functions as a metal chelating
compound in plant tissues, binding metal ions so they can be transferred throughout the plant.59

Figure 7 Nicotianamine structure

	
  

Other possible roles include protecting plants from oxidative stress.60 Recent studies have shown
that NA possesses antihypertensive effects, which are related to its ability to inhibit the
angiotensin I-converting enzyme (ACE) in the renin-angiotensin system.61 Pharmacological ACE
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inhibitors are widely used for the control of high blood pressure, as well as in the treatment of
diabetic neuropathy and hypertensive related congestive heart failure. The ACE enzyme must
bind zinc in each active site for catalytic activity, leading to speculation that NA inhibited ACE
activity via zinc chelation. However, recent studies have shown that NA shows preferential
inhibition towards ACE. In one study, NA had a similar inhibition rate as the known metal
chelator EDTA for the zinc-containing enzyme carboxypeptidase A.61 However, NA had a 15
times higher inhibition rate for ACE than EDTA.61 NA has also shown great
Table 1 Reported Enriched Sources of Nicotianamine
Species	
  
Datura	
  metel	
  	
  
Lycium	
  chinense	
  
Solanum	
  melongena	
  
Lycopersicon	
  esculentum	
  
(tomato)	
  
Nicotiana	
  tabacum	
  B.	
  Y.	
  
(tobacco)	
  
N.	
  glutinosa	
  (tobacco)	
  
N.	
  rustica	
  (tobacco)	
  
	
  
N.	
  arentsii	
  (tobacco)	
  
N.	
  alata	
  (tobacco)	
  
N.	
  debneyi	
  (tobacco)	
  
Zea	
  mays	
  
Rohdea	
  japonica	
  
Fagus	
  silvatica	
  (beechnuts)	
  	
  
Soybeans	
  	
  

Reported	
  Yield	
  of	
  NA	
  (μmol/g	
  fr.	
  Wt)	
  
0.12	
  	
  
0.69	
  	
  
0.05	
  	
  
0.05	
  	
  
0.05	
  	
  
0.07	
  
0.19	
  
	
   0.12	
  
0.03	
  
0.13	
  	
  
0.02	
  	
  
trace	
  
Not	
  reported	
  
0.3	
  %	
  aqueous	
  extract	
  of	
  soybeans	
  

promise as a replacement for EDTA as a food additive to prevent spoilage.62 Certain plant
species have greater levels of nicotianamine in their tissue (Table 1).63,64
Metal ions can act as catalysts for oxidative reactions that can cause spoilage in food
products. EDTA is a synthetic chelator that is presently added to many food products to
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sequester metal ions and prevent oxidative reactions. Utilizing NA as a natural metal chelator
could allow companies to label food products as “all-natural” or organic and the market for these
food products is continuing to increase.65
Although all higher plants contain NA, two groups of plants, graminaceous and nongraminaceous, can be differentiated based on NA use. Graminaceous plants use it as a precursor
in the biosynthetic production of the mugineic acid family of phytosiderophores, while nongraminaceous plants do not utilize this pathway.

Graminaceous plants that thrive in iron

deficient conditions show a higher degree of plasticity in regards to the NA synthase gene.66
Another important distinction between plants with regards to NA production relates to plants
involved in metal hyperaccumulation.

Thlaspi caerulescens can thrive in soil with

concentrations of nickel that would be toxic to other plants, and more NA is produced and
resistance to high nickel soil concentrations is conferred when the NA synthase gene from T.
caerulescens is spliced into Arabidopsis thaliana.67 All of these considerations can be taken into
account when deciding on source material for NA extraction. Iron deficient conditions would
only need to be utilized if the plant species is both graminaceous and adaptive to iron deficient
conditions. Soybeans and soy flour are readily available products which could be used to
generate high yields of nicotianamine to replace EDTA in food products.
The Hepatitis C Virus
The hepatitis C virus (HCV) is responsible for chronic hepatitis C which can lead to
cirrhosis of the liver and liver cancer and affects between 130-170 million people in the world
today.68 More than 350,000 people die from chronic hepatitis C annually and an estimated 3-4
million people are infected with HCV each year.68 About 25% of people in the United States
who are infected with the human immunodeficiency virus (HIV) are also infected with HCV.68
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Co-infection with HIV increases the risk of developing liver disease more than three fold.69
There have been numerous studies showing that while HCV is primarily hepatotropic, it can also
replicate in immune cells.70
Serological tests were devised in the 1970s to detect both hepatitis A and B, leading to
the discovery that an unknown, unidentified virus was responsible for many cases of viral
hepatitis.71 In 1989, an immunoscreening approach which utilized a cDNA library created from
clones of nucleic acids from HCV infected chimpanzees led to the identification of the hepatitis
C virus.72 In 1991, the first detailed study of the genome reported a 9379-long nucleotide
sequence with a large open reading frame (ORF) that was predicted to encode a large polyprotein
containing 3011 amino acids.72 HCV was classified as a member of a new genus in the
Flavivirus family; this family contains two other genera that encode a large polyprotein
subsequently cleaved at multiple sites.73 There has been a persistent problem in culturing HCV in
vitro, prompting researchers to rely heavily on cDNA technology to study HCV. In 1993, a
heterologous system using vaccinia viruses was used to elucidate the polyprotein cleavage
products.73 In 1997, it was formally proved that HCV is the sole causative agent of hepatitis C by
infecting chimpanzees with HCV cDNA.74
A constant barrier to HCV drug development has been the absence of successful
culturing methods for detailed studies of the life cycle. There have been multiple techniques
developed and refined over recent years to overcome this obstacle. One technique involves
psuedotyping viral particles (HCVpp) with the E1 and E2 envelope glycoproteins to study host
cell entry. Early reports using this technique utilized modified proteins which were poorly
infective, however HCVpp were later reported which harbored unmodified glycoproteins and
were highly infective.75 The complete culturing of HCV (HCVcc) by transfecting hepatoma-
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derived cell lines has also recently been achieved and refined, allowing for detailed studies of the
HCV life cycle.76 These new techniques have allowed for a number of directly acting antiviral
(DAA) agents to be developed which target specific proteins in the life cycle. Natural products
screening programs can use these targets to screen for novel inhibitors of HCV.
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CHAPTER TWO:
SECONDARY METABOLITE PRODUCTION FROM A BACILLUS AMYLOLIQUEFACIENS
ENDOPHYTE OF PLATANUS OCCIDENTALIS
Endophytes are microbes that inhabit plant tissue without causing disease. One of the
functions of endophytes as part of a symbiotic mutualism with plants involves participating in
defense mechanisms whereby the microbe produces antibiotics, antifungals, and growth
promoting/inhibiting agents. Here, we show that a Bacillus amloliquefaciens endophyte
produces rapamycin for its plant host Platanus occidentalis and this molecule is then possibly
biotransformed to yield a putative rapamycin analog. MALDI-IMS of the endophyte colonies
and extraction and purification of liquid endophyte cultures showed rapamycin production by B.
amyloliquefaciens. Extraction of host tissue produced the putative rapamycin analogue. Iturin A3
production was indicated by LC-MS from healthy stem tissue of the host plant and from liquid
fermentation of the endophyte. Thus, the endophyte and Platanus occidentalis host are involved
in a mutualism in which the endophyte produces rapamycin which is possibly modified by the
host plant and also produces iturin A3 which could be isolated from the host plant. This is the
first report of rapamycin production from a new source since its original discovery from an
Easter Island soil Streptomyces hygroscopicus in 1975 and reveals a significant ecological role
for this highly important natural product.40-41 The data presented here illustrates a significant
potential for discovery via silent gene expression. This is also the first report of a mutualistic
relationship between B. amyloliquefaciens and P. occidentalis, a potential biomass crop for the
southeastern United States.
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Endophytes are microbial species which live inside of plant tissue without causing
disease and all plant life is thought to harbor some species of endophytes. Endophytes have the
ability to contribute to plant health in a multitude of ways.77-78 One function of endophytes is the
participation in a mutualism whereby endophytic microbes produce antimicrobial and antiviral
secondary metabolites that benefit the host plant as defense mechanisms while consuming plant
produced carbohydrates.79 Novel and known compounds originally isolated from plant sources,
with antimicrobial, immunosuppressant, and anticancer activity have been isolated from
endophytes.80 Here, we show that a B. amyloliquefaciens from a common plant species produces
rapamycin. The genome sequenced using Illumina software and assembled using Geneious
software by mapping assembly using B. subtilis reference sequence NC_000964.3.81-82 This has
been a reference genome for more than 10 years and current annotations suggest B. subtilis is an
epiphyte.81 Interestingly, low sensitivity and fast speed settings on Geneious genome assembly
software gave much different results and showed the Bacillus endophyte to be much more
closely related to B. subtilis then when settings were changed to higher sensitivity settings
(Table 2). The endophyte was fermented under a number of different conditions and only one
certain group of culture ingredients supported the detection of rapamycin production. This was
CS20 medium, a medium originally developed for the culturing of fastidious organisms.83
MD5FL which had been used for rapamycin production by S. hygroscopicus did not support
production,84 nor did the traditional Bacillus Landy’s medium, or CHARD2, a medium that was
developed to mimic the conditions of xylem plant tissue.85 Iturin A3 could be shown from both
endophyte cultures and P. occidentalis extracted stem tissue. However, rapamycin could not be
detected in plant host tissue. This led to our hypothesis that rapamycin was possibly being
biotransformed to a currently unknown molecule by the plant host.	
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Table 2 Bacillus genome assembly
Bacterial	
  
species	
  
Bacillus	
  
subtilis	
  	
  
Bacillus	
  
endophyte	
  	
  
Bacillus	
  
endophyte	
  
	
  

Sequence	
  
length	
  
4,215,606	
  

High	
  
quality%	
  
-‐	
  

Identical	
  
sites	
  	
  
-‐	
  

Ambiguities	
  	
   Sensitivity/speed	
  
-‐	
  

-‐	
  

4,214,756	
  

66.5%	
  

25.2%	
  

1,411,866	
  

low/high	
  

3,315,554	
  

98.9%	
  

15.3%	
  

51,780	
  

high/low	
  

Figure 8 Production of rapamycin and possible biotransfromation to a putative rapamycin
analogue (A) P. occidentalis leaf tissue. (B) MRSA-active glycosides from leaf tissue.2 (C) P.
occidentalis stem tissue. (D) Wounded stem tissue. (E) B. amyloliquefaciens emerging from
stem tissue. (F) Isolated B. amyloliquefaciens after excision from solid agar and transfer onto
MALDI plate. (G) MALDI-IMS of protonated rapamycin signal from B. amyloliquefaciens
colony. (H) Rapamycin structure. (I) LC-MS of product of putative biotransformation product
and rapamycin standard.
Stem tissue material was collected from P. occidentalis species and, after surface
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sterilization, the outer bark was removed to expose the vascular cambium layer and xylem tissue
to solid malt-based agar (Figure 8 C-E). Within 48 hours, bacterial and fungal growth could be
detected emanating from host tissue (Figure 8 E). The colony morphology of bacterial growth
showed characteristics of Bacillus sp. including an undulate margin and irregular shape (Figure
8 F).

Figure 9 Isolation of iturin A3 from B. amyloliquefaciens and P. occidentalis host. (A) EIC from
LC-MS monitoring the mass for the sodium adduct for iturn A3 at m/z 1079.6 [M+Na]+ from the
crude ethanol extract from a B. amyloliquefaciens culture and methanol extract from P.
occidentalis stem material. (B) Stems of P. occidentalis. (C) B. amyloliquefaciens emerging
from stem tissue. (D) Isolated B. amyloliquefaciens after excision from solid agar and transfer
onto MALDI plate. (E) MALDI-IMS of sodium adduct of iturin A3 [M+Na]+.
(F) HRMS and NMR of iturin A3. (G) Structure of iturin A3.	
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Figure 10 Isolation of rapamycin from B. amyloliquefaciens

	
  

	
  
	
  

	
  
Figure 11 FTMS of rapamycin standard. Ions are rationalized by successive losses of water and
methanol in certain combinations. Structures are coordinated with arrows by color.
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Figure 12 FTMS of purified fraction from B. amyloliquefaciens. Ions are rationalized by
successive losses of water and methanol. Structures are coordinated with arrows by color. Ions
that match rapamycin standard FTMS are highlighted.

MADLI-IMS of bacteria over seven days showed production of rapamycin with the
protonated signal being detected after day two (Figure 8 G). Interestingly, rapamycin production
clearly stayed in the boundaries of the colony which strongly contrasted with the production of
iturin which was excreted from the colony (Figures 8 G & 9 E). Processed P. occidentalis
xylem material showed a putative rapamycin analogue at m/z 935.7337 (Figure 8 I).
Iturin A3 was shown from both endophytic B. amyloliquefaciens liquid cultures and
directly from host P. occidentalis stem tissue (Figure 9). The signal for the sodium adduct of
iturin A3 was detected by LC-MS in an ethanol extract from a B. amyloliquefaciens culture as
well as a methanol extract from processed stem material from P. occidentalis (Figure 9 A).
Bacillus cultures were isolated directly from stem tissue and MALDI-IMS revealed the signal for
the known Bacillus metabolite as iturin A3 (Figure 9 C-E). Purification allowed for recording
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NMR and HRMS data, which confirmed iturin A3 from endophyte cultures (Figure 9 F).
Isolation of rapamycin from B. amyloliquefaciens followed the scheme shown in Figure
10. FTMS of liquid cultures of the B. amyloliquefaciens endophyte when compared to FTMS of
a rapamycin standard verified that the detected signal by MALDI-IMS and LC-MS was
rapamycin (Figures 11 & 12).
For example, it has been shown that with secondary metabolite production from
filamentous fungi, it is important to have a media that is rich in amino acids, vitamins, and trace
metals.86 The carbon source can also play an important role in the secondary metabolite
production of both bacteria and fungi.87 In our studies, a media that had originally been
developed for the culture of Xylella fastidiosa was used (Table 3).83
Table 3 CS20 Media83
Distilled	
  H2O	
  
Soy	
  peptone	
  
Bacto	
  tryptone	
  
(NH4)2HPO4	
  
Hemin	
  Cl	
  (0.1%)	
  
KH2PO4	
  
MgSO4	
  .7H2O	
  
L-‐glutamine	
  
Dextrose	
  
Starch,	
  potato	
  soluble	
  
L-‐histidine	
  
Phenol	
  red	
  (0.2%)	
  
pH	
  

1	
  L	
  
2.0	
  g	
  
2.0	
  g	
  
0.85	
  g	
  
15.0	
  mL	
  
	
  
0.4	
  g	
  
6.0	
  g	
  
1.0	
  g	
  
2.0	
  g	
  
1.0	
  g	
  
5.0	
  mL	
  
6.6-‐6.7	
  

1.0	
  g	
  

	
  

As stated previously, the colony morphology of the sample was undulate with an
irregular margin which conforms with the general description of the Bacillus genus (Figure
13).10
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Figure 13 B. amyloliquefaciens morphology.	
  	
  The colony morphology is undulate with
an irregular margin. Image taken after colonies had been transferred to MALDI plate from solid
agar.
B. amyloliquefaciens colonies were grown in CS20 media83 and, in order to test for
bioactivity, extracts were assayed for activity against pathogenic bacteria and fungi, malaria, and
leishmaniasis using the NCNPR in-house screening protocol. Although the first round of
bioassay results were not encouraging, the project was continued due to the mistaken belief that
we were dealing with a plant pathogen which would make the study of any secondary metabolite
production, regardless of activity, important.
It was decided to continue this project, but start doing chromatography with extracts to
get to higher levels of purity in hopes that more purified extracts would yield better activity.
VLC with a number of different chromatography column materials including normal phase using
silica gel (Silicycle Siliaflash® F60, particle size 40-63µm), size exclusion using Sephadex®
LH-20, and reverse phase using C18 (SiliCycle C18, Carbon 17%, particle size 40-63 µm) were
used. The first significant bioactivity results was retrieved from after a 1 L culturing of the
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Bacillus amyloliquefaciens followed by reverse chromatography using the fractionation scheme
in Figure 14.

Figure 14 Culturing and purification of endophytic Bacillus secondary metabolites.

	
  

Table 4 MRSA and Staph. aureus activity
Fraction 1 (100% H2O)
Fraction 2 (75% H2O, 25% MeOH)
Fraction 3 (50% H2O, 50% MeOH)
Fraction 4 (25% H2O, 75% MeOH)
Fraction 5 (100% MeOH)
!

IC50 Staph aureus IC 50 MRSA
0
0
0
0
0
0
0
13.35
14.1
12.75

The IC50 values for extracts 4 (25% MeOH, 75% H2O), and 5 (100% MeOH) were
significant (Table 4). Fraction 5 was analyzed by LC-MS. Strong signals were seen at m/z
1492.2 along with other signals clustered around this signal ranging from m/z 1461.1 to 1506.2
(Figure 15). These signals correlate with the known Bacillus metabolites the fengycins.
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Fengycin lipopeptides are produced by non-ribosomal peptide synthetases (NRPSs) or through
hybrid polyketide synthetases and non-ribosomal peptide synthetases (PKs/NRPSs) which can
lead to multiple isoforms being produced naturally in B. subtilis as B. amyloliquefaciens
extracts.88 They possess antibacterial activity.24

	
  
Figure 15 Fengycin ions. Formulas are noted and match a number of different fengycin
isoforms.

All fengycins are decapeptides; different amino acids within the eight amino acid
cyclized peptide moiety along with changes in length, branching, and saturation of the fatty acid
tail are responsible for slight modifications in fengycin secondary metabolites. Members of the
fengycin A family have the following amino acid sequence: Glu-Orn-Tyr-Thr-Glu-Ala-Pro-GlnTyr-Ile. Fengycin B isoforms have a valine substituted for alanine (Figure 16). Other isoforms
exist and new ones continue to be discovered.89 Rapid methods using FTMS have been
developed to discern which fengycin metabolites are being observed as there can be significant
overlap in [M+H]+ ions from one family to another depending on amino acid substitutions and
fatty acid chain composition.90 All ions that were found have previously been reported from
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fengycin-producing Bacillus spp.91 Another cluster of ions was seen in fraction five between m/z
1008.9 to m/z 1044.9 (Figure 17). These signals correlate with the known Bacillus secondary
metabolites the surfactins.17,91 These are heptapeptides with some heterogeneity at different
positions in the peptide moiety. All members are lactones and are linked to a fatty acid tail that
can vary in length (Figure 18).
The final known lipopeptide family of molecules that are produced by Bacillus spp. are
the iturins. The iturins contain seven cyclized amino acids moieties and a β-amino fatty acid.
They are differentiated by variations of amino acids at different positions and also by variation in
the branching or length of the β- amino fatty acid.29 A cluster of signals correlating with the
iturin molecules was seen by LC-MS (Figure 19). As with other previously discussed Bacillus
lipopeptides, there can be significant overlap between different isoforms and homologues when
trying to decipher exactly which molecule is being observed and MS/MS methods are often used
for this purpose.
Fraction 5 was put through HPLC to further purify Bacillus metabolites (Figure 20). UV
wavelengths of 215 nm and 254 nm were used to analyze the samples. Two sharp signals were
seen at 215 nm (Figure 21). These correlated with two iturin homologues (Figure 22). HRMS
and NMR showed these to be iturin A2 and iturin A3 (Figure 23). As noted previously, it is
important to use MS/MS methods for full identification of iturin peptides. Therefore, only
purified metabolites were assigned completely. Numerous publications dealing with lipopeptide
production have assigned these metabolites using MS/MS.
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Figure 16 Fengycin isoforms (A) Fengycin A contains alanine in the indicated position. (B)
Fengycin B contains valine in the indicated position. Many different members of both families
are found based on differences in length and saturation in the fatty acid tail.

	
  
Figure 17 Surfactin ion signals. Formulas are noted and match many different surfactin
isoforms.
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Figure 18 Surfactin homologues. (A) differs from structure (B) by a methylene unit.
	
  
	
  

Figure 19 Iturin ions.
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Figure 20 Iturin isolation scheme

Figure 21 Purification of iturin homologues
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Figure 22 Iturin homologues.	
  	
  Structure (A) differs from structure (B) by a methylene unit.
Structure (A) represents iturin A2. Structure (B) represents iturin A3.

	
  
Figure 23 Purified iturin homologues. (A) HRMS for iturin A3. (B) NMR for iturin A3. (C)
HRMS for iturin A2. (D) NMR for iturin A2.
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Figure 24 EIC of bacterial extract and rapamycin standard.	
  	
  Bottom panel shows three signals
found in bacterial extract including m/z 931.6 [M+NH4]+, m/z 936.6 [M+Na]+,
and m/z 952.6 [M+K]+ adducts.
A signal was observed in fraction 4 which correlated with the ammonium adduct of
rapamycin at m/z 931.6. It was decided to use a rapamycin standard (LC Laboratories Cat. No.
R-5000) to confirm that the signal was a rapamycin ammonium adduct by comparing the
retention time of the standard to the ion found in the c18 fraction (Figure 24).
A series of MALDI-IMS experiments were performed on the Bacillus sp. to test for
rapamycin production. In order to perform these experiments, the first step was to design the
sample preparation steps so that consistent results could be obtained. This step was particularly
important as sample preparation is the step that introduces the most variability and can lead to
difficulty in reproducing results in MALDI-IMS.92 The first process that needed to be developed
was to be able to excise colonies from solid agar plates and place them on a Bruker MTP 384
steel plate, being careful to not let any air bubbles form between the excised colony and the steel
plate. After this technique had been developed, it was important to test different thicknesses of
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agar for the colonies to grow on, as it has been proven that a thinner sample improves peak
intensity as well as the signal to noise ratio.93 However, the agar could not be too thin as the
excised colony after matrix application had to be dehydrated prior to data acquisition and a
sample that was too thin would not permit a vacuum to be applied for drying. After a period of
trial and error, the following protocol was developed.
Seven CS20 agar plates were poured with days 1-5 poured with 10 mL of agar and plates
for days 6 and 7 poured with 15 mL of agar. Five µL of Bacillus sp. containing glycerol stock
was placed in the center of each of these plates and placed in an incubator at 36°C. One plate
was removed every 24 hours and colonies were excised from the agar plate and placed on a
Bruker MTP 384 steel plate. After a picture of the colony was taken for later overlay using
imaging software, alpha-cyano-4-hydroxycinnamic acid matrix was shaken on top of the colony
using a 20 µm sieve for even distribution of the matrix. The steel plate was then placed in an
incubator at 36 °C for four hours. Afterwards, the plate was placed in a desiccator. The
desiccator was then placed under vacuum for 5 minutes and then sealed and the plate was left
inside for an additional 25 minutes. The plate was then removed and placed into a Bruker
Autoflex II mass spectrometer equipped with the Compass 1.1 software suite (consisting of
FlexImaging 3.0, FlexControl 2.4, and FlexAnalysis 2.4). The samples were analyzed in linear
positive mode with 200 µm intervals. The spectra were collected in the m/z 700-1600 range at a
200 Hz laser frequency. After data acquisition, the data was analyzed using FlexImaging
software.
The data acquired and analyzed after repeating this procedure for a time course
experiment of seven days are shown in Figure 25. The top panel shows the bacterial colony
after being placed on the steel plate before the matrix was applied (note that days 3 and 5 are
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omitted as there was a problem with transferring a colony from agar to plate). The horizontal
panel below this shows an ion at m/z 914.6 which correlates with the [M+H]+ ion of rapamycin
which has a monoisotopic mass of m/z 913.555. The third panel from the top shows the
dehydration product for rapamycin at m/z 895.7. Finally, the lower panel shows the potassium
adduct at m/z 952.3.

	
  
Figure 25 MADLI-IMS of Bacillus endophyte.	
  	
  Top panel shows bacterial colonies prior to
matrix application. 2nd panel from top shows production of putative rapamycin signal at m/z
914.6 [M+H]+. 3rd panel shows dehydration product at m/z 895.7 [M-H20]+. 4th panel shows
potassium adduct at m/z 952.3 [M+K]+.
In order to confirm the mass signal was rapamycin, an attempt was made to culture enough
bacterial material to generate an NMR spectrum that could be overlaid with a rapamycin
standard NMR spectrum. Figures 26 and 27 show the fermentation protocols that were followed
with the highlighted fraction containing the putative rapamycin signal. In order to further test if
retention times for rapamycin would match the putative rapamycin metabolite, standard
rapamycin was injected on a Phenomenex Luna 5u C18(2) 250 x 21.20 RP column. A gradient
was run that started 15 minutes after injection and ran over an hour from 95% H2O/ 5% MeCN to
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100% MeCN. The retention time was approximately 78 minutes. Note that UV data are not
shown as rapamycin contains a weak chromophore consisting of a conjugated triene system with
a peak intensity at 278 nm and the bacterial extract did not show UV absorption. Instead, the
putative bacterial rapamycin molecule was isolated by using the retention time that had been
shown from the standard rapamycin. Approximately 20 mgs of the fraction containing
rapamycin signal were injected following the same parameters that had been used for the
standard.

Figure 26 Isolation scheme for rapamycin
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Figure 27 Isolation scheme for rapamycin
The fraction that was collected at 78 minutes could not be analyzed by NMR
spectroscopy due to a low amount of material, however LC-MS confirmed that the putative
rapamycin molecule from the Bacillus sample eluted at the same time as rapamycin. (Figure 28).

Figure 28 HRMS of rapamycin from Bacillus sp.
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Figure 29 HRMS of rapamycin standard

	
  

Note that rapamycin standard has higher ppm value than Bacillus product. Both
of these values were within the accepted range for error values with the rapamycin formula of
C51 H79 N O13. These values were calculated by subtracting the observed mass from the
calculated mass, dividing this number by the calculated mass, and then multiplying by 106. For
the Bacillus product this equation [(936.5449-936.5433)/936.5449] * 106. For the rapamycin
standard this was [(936.5449-936.5376)/936.5449] * 106.
These two molecules can be noted as identical based on these masses. However, it was
important to gather NMR data to attempt to overlay the two spectra as a number of molecules
can have identical monoisotopic masses. This data was gathered after multiple HPLC
purifications were ran using the same procedures that have been previously outline for iturin
purification.
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Figure 30 Rapamycin and B. amyloliquefaciens fraction 1H-NMR overlay experiment. Green
chemical shifts represent rapamycin standard (CDCl3). Red chemical shifts represent purified
metabolite from B. amyloliquefaciens (CDCl3).
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Figure 31 Rapamycin and B. amyloliquefaciens fraction 1H-NMR overlay experiment. Green
chemical shifts represent rapamycin standard (CDCl3). Red chemical shifts represent purified
metabolite from B. amyloliquefaciens (CDCl3). Range is 2.4 ppm – 0.4 ppm.

	
  
Figure 32 Rapamycin and B. amyloliquefaciens fraction 1H-NMR overlay experiment. Green
chemical shifts represent rapamycin standard (CDCl3). Red chemical shifts represent purified
metabolite from B. amyloliquefaciens (CDCl3) Range is 5.0 ppm – 2.5 ppm.
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Figure 33 Rapamycin and B. amyloliquefaciens fraction 1H-NMR overlay experiment. Green
chemical shifts represent rapamycin standard (CDCl3). Red chemical shifts represent purified
metabolite from B. amyloliquefaciens (CDCl3). Range is 6.4 ppm - 4.9 ppm.
	
  
HRMS is shown for the rapamycin standard to compare to the isolated rapamycin signal
(Figure 29). After multiple purifications using HPLC, enough material was purified to obtain
some NMR spectroscopic data. An overlay of rapamycin standard (green) and rapamycin from
Bacillus sp. (red) show the same chemical shifts for many signals from both fractions (Figure
30). Expansions focusing on chemical shifts from 0.4 ppm to 2.4 ppm (Figure 31), 2.4 to 5 ppm
(Figure 32), and 4.9 to 6.4 ppm (Figure 33) clearly show signals that are overlain between
rapamycin and the B. amyloliquefaciens product.Another experiment was done to further
understand the relationship between the endophyte and the host P. occidentalis. P. occidentalis
tissue was extracted and analyzed by LC-MS in order to test whether or not metabolites that had
been located in bacterial extracts could also be found in plant host tissue. Three P. occidentalis
extracts analyzed were analyzed: healthy leaf tissue, leaf tissue from a plant host infected with

	
  

41	
  

Xylella fastidiosa, and wood tissue from a healthy specimen. Each tissue sample was extracted
successively with hexanes, chloroform, and methanol.
Table 5 Extracts of P. occidentalis tissue
Chloroform ext.
(mg)
6.1

Methanol ext.(mg)

Symptomatic leaf (1.06 g)

Hexanes
ext.(mg)
7.3

Asymptomatic leaf (0.892 g)

6.4

5.5

4.5

Asymptomatic stem tissue (1 g)

2.4

1.9

9.6

3.8

Figure 34 Overlay of two extracted ion chromatograms of P. occidentalis extract and
endophytic extract. The m/z 1079.6 signal matches with previously purified iturin A3.

	
  

The total weights for these extracts are collated in Table 5. These extracts were analyzed
using LC-MS. The MeOH extract shared the same signal at m/z 1079.6 and the same retention
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time (Figure 34). This was the same signal that had previously been purified and solved by
NMR and HRMS as iturin A3.

	
  
Figure 35 Extraction of P. occidentalis wood material	
  

	
  
Figure 36 Two EICs of putative rapamycin analog and rapamycin. Top panel shows EIC of m/z
913.7 from chloroform extract from P. occidentalis and middle panel shows EIC of sodium
adduct of rapamycin at m/z 936.6 [M+Na]+. Bottom panel shows signal for protonated signal at
m/z 913.7, sodium adduct at m/z 935.7 and potassium adduct at m/z 951.7 for unknown.
In order to complete a set of challenge experiments using MALDI-IMS, P. occidentalis
wood material was ground to a fine sawdust material and extracted successively with hexanes,
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chloroform, and methanol (Figure 35). Although no rapamycin adduct signals were found in
any of the P. occidentalis wood extracts, another signal was found in the chloroform extract
which was very close in mass to the rapamycin signal (Figure 36).

In order to establish if this

was a rapamycin analogue, the chloroform extract was further purified following the procedure
outlined in Figure 37. After purification, 5 mg of the purified extract was further resolved by
HPLC monitoring the UV absorption maximum for rapamycin at 278 nm (Figure 38).

Figure 37 Isolation of putative rapamycin analogue
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Figure 38 Putative rapamycin analogue purification.	
  	
  UV wavelength is 278 nm.

Figure 39 HRMS of putative rapamycin analog.

	
  

Fractions were analyzed after HPLC by direct injection and the indicated signal contained the
putative rapamycin analogue. HRMS for this signal was gathered and this fraction was
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submitted for FTMS (Figure 39).
As was seen in earlier parts of this thesis and is documented in numerous publications,
achieving reliable microbial production of secondary metabolites can be problematic. One of the
strategies for trying to help solve this problem is to try and develop an understanding of how the
plant host regulates secondary metabolite production from the endophyte. A series of
experiments was designed using MALDI-IMS to test if extracts of P. occidentalis would upregulate iturin metabolites that had been characterized from the Bacillus sp. There was a
significant risk that the solvent used for extraction (either hexanes, chloroform, methanol) would
cause problems in bacterial growth and lead to differences in secondary metabolite production
that could be interpreted as the P. occidentalis host regulating the Bacillus sp. endophyte as a
false positive. Therefore, the first experiment was a time course experiment that involved plating
a 5 µL B. amyloliquefaciens glycerol stock onto a series of seven different CS20 plates and
surrounding these newly plated colonies with 10 µL of each solvent at approximately the same
distance from different sides of the colony. These plates were incubated at 36 °C and monitored
for growth. After four days bacteria had grown over all three solvents. The bacterial margin did
not show any variability depending on whether or not it expanded over the areas where solvents
had been placed and iturin production was uniform throughout the colony area (Figure 40). The
next step was to test the extracts to see that, when the endophyte colony came into contact with
one or more of the host plant extracts, iturin production increased. This was done by designing a
time course experiment which involved plating 5 µL of glycerol stock of the endophyte in the
center of 5 different CS20 solid agar plates. These were then surrounded by the three different
P. occidentalis extracts on three different sides of the colony. Extracts were generated by
successively extracting host wood material with hexanes, chloroform, and methanol (Figure 41).
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These extracts were re-dissolved in the original solvent using a pre-calculated volume so that 10
µL of liquid extract would equal half a milligram of extract. These were placed in such a way
so that, over the five day period, the bacterial colony would expand to eventually come in contact
with the extracts. It was important to have the extracts placed sufficiently far away to allow for
imaging the colony before it reached the extracts but also not too far away as to prevent the
colony reaching the extracts in 5 days. On day one the colony is expanding but has not yet
reached the edge of any of the extracts and the intensity of iturin production is fairly uniform
throughout the colony and outside the colony (Figures 42 & 43). On day three there the colony
has come closer to all extracts and there seems to be a slight increase in iturin intensity as a solid
band as it is coming into contact with the chloroform extract (Figures 44 & 45).

	
  
Figure 40 MALDI-IMS iturin blank run.	
  	
  Bacillus sp. were analyzed by MALDI-IMS to
ascertain if solvents affected either iturin production or Bacillus growth. Iturin signal is shown
as green. (H) hexanes, (C) chloroform, (M) is methanol. (PB) is agar piece that bacterial colony
was extracted from. (B) is a separate agar plate of same media composition.
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Figure 41 Extraction of P. occidentalis for MALDI-IMS challenge experiment

	
  

	
  
Figure 42 Bacillus sp. colony surrounded by host P. occidentalis extracts.(H) is hexane
extract,(C) is chloroform extract, (M) is methanol extract. Colony and extracts were excised
after one day. (PB) is agar piece that bacterial colony was extracted from. (B) is a separate agar
plate of same media composition.
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Figure 43 Day one iturin production.	
  	
  Iturin intensity is relatively uniform throughout with the
exception that more signals are found excreted from the colony. Hexanes and chloroform
extracts possibly inhibit iturin production. (PB) is agar piece that bacterial colony was extracted
from. (B) is a separate agar plate of same media composition.

	
  
Figure 44 Bacillus sp. colony surrounded by host P. occidentalis extracts. (H) is hexane extract,
(C) is chloroform extract, (M) is methanol extract. Colony and extracts were excised after three
days.
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Figure 45 Day three iturin production. There is slight increase in iturin intensity as the Bacillus
colony comes into contact with the chloroform extract.

A clear increase in iturin production can be seen on day four after the Bacillus extract has
come into contact with the chloroform extract (Figure 46). This is seen clearly by representing
the data in a different fashion using a heat map-like representation. The inset shows which
colors represent higher intensities with blue being the lowest intensity and red being the highest.
All throughout the colony the intensity of the signals is mostly uniformly blue with higher
intensities interspersed throughout the colony. However, as the Bacillus colony comes into
contact with the chloroform extract, the signals are clearly much more intense with more areas of
green and there is red interspersed within green (Figure 46). These results suggest something
within the host chloroform extract is eliciting iturin production from B. amyloliquefaciens.
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Figure 46 Day four iturin production. The left panel shows the B. amyloliquefaciens colony
coming into contact with the chloroform extract. The middle panel shows there is a substantial
increase in iturin intensity as the Bacillus colony comes into contact with the chloroform extract.
This is highlighted by using a heat-map representation in the right panel. The inset shows how
color relates to intensity.
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CHAPTER THREE:
PURIFICATION OF NICOTIANAMINE FROM SOY FLOUR
	
  

Figure 47 Nicotianamine structure

	
  

Nicotianamine is a chelator of metals found in plants that has the ability to replace EDTA
in food products to prevent spoilage.62 Because nicotianamine is ubiquitous among plant species,
options for finding a viable source are broad. After searching for nicotianamine production and
yields, soybeans and soybean products were chosen for the initial attempt to isolate significant
amounts. The samples that were retrieved for analysis included whole commercially produced
soybeans from five different hybrid species of whole soybeans and soy flour.
Whole soybean analysis. The commercially available Asgrow 4531 strain soybeans
(1.785 kg) from Monsanto-Asgrow brand markets in Leland, MS, were ground and soaked in 8
L warm water (40 °C) for roughly 20 hours, and subjected to sonication. The aqueous extract (6
L) was removed from the soybean material by use of mesh wiring filtration. Using a 1 M HCl
solution, the pH of the resulting aqueous extract was adjusted to 4.5 to precipitate proteins. Using
centrifugation, the proteins from the pellet were removed from the aqueous extract. A total of
5.5 L of supernatant was recovered and subsequently concentrated to 2.25 L using rotary
evaporation. 2.25 L of ethanol was added to the concentrated aqueous extract in order to
precipitate the nicotianamine-containing material. The mixture was stirred and placed under
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refrigeration overnight to maximize precipitation. The resulting mixture was centrifuged to
separate the precipitate from the aqueous extract. The precipitate was lyophilized and yielded 15
g of dry material.
Soy flour analysis. Soy flour was obtained from a 1.5 lb (680 g) bag of Hodgson Mill
soy flour exp. date 11/10/12, barcode: 0 71518 05039 9. To two 2800 mL flasks were added 200
g of the flour. Water (2500 mL) was added to each and the pH was adjusted to 9 using sodium
hydroxide and set to stir at 25 °C. The suspension was filtered using wire mesh filtration and the
pH was adjusted to 4.5. The aqueous extract was centrifuged and the protein-containing pellet
was removed. Ethanol was added to the supernatant at a concentration of 80%. The resulting
solution was centrifuged and the nicotianamine-containing pellet was removed. The material was
lyophilized to yield 12.4 g of dry material and nicotianamine was detected by LC-MS and
compared to material generated from whole soybeans.

Table 6 Calibration of NA using LC-MS
Nicotianamine (ng)
210

420

1050

2100

4200

Area

Average area

1350
1195
1127
3579
3933
3524
9600
10565
10578
22021
24154
21284
39385
40431
43794

*RSD (%)=((std dev*100)/mean)
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RSD

1224

9.34

3679

6.03

10248

5.47

22486

6.63

41203

5.59

Figure 48 Calibration curve for nicotianamine

	
  

The first step in being able to quantify the yield of nicotianamine using LC-MS was to
create a calibration curve using a nicotianamine standard. Five different concentrations were
used and each concentration was run three times (Table 6). The average of three runs for each
concentration were used to create a calibration curve which could be used to compare all future
extracts for highest yielding methods (Figure 48). Another important piece of data to generate
was the detection limits of the LC-MS as well as the HRMS. The detection limits were found to
be approximately 4.2 ng (Figure 49) and the HRMS showed an [M+H]+ ion at m/z 304.1431.
(Figure 50).
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Figure 49 Detection limits of nicotianamine.	
  	
  4.2 ng was the lowest amount that could be
detected.

Figure 50 HRMS of nicotianamine.

	
  

After this data had been gathered, the yield from the two different sources could be
quantified. A comparison of the yield between whole soybeans and soy flour, which had been
defatted, proved that soy flour was the optimal soy resource. The ionization intensity of the
extracted [M+H]+ ion at
m/z 304.1431 for nicotianamine is shown for the whole soy precipitate, soy flour precipitate and
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the nicotianamine standard (Figure 51). The integration intensity of extracted ion m/z 304.1431
m/z for 20 µg soy flour precipitate, 20 µg whole soy precipitate, and 50 ng of pure nicotianamine
standard was 621051, 228178, and 603387, respectively. The following equations give the
percent composition of nicotianamine in the precipitate mixtures:
A. [(50 ng pure NA * 621051) / (603387)] / (20000 ng crude precipitate) * 100% =
0.26% NA in soy flour precipitate.
B. [(50 ng pure NA * 228178) / (603387)] / (20000 ng crude precipitate) * 100% = 0.1%
NA in whole soy precipitate.
Based on this analysis, it was decided that soy flour was the best viable option to attempt
to purify nicotianamine. The Kikkoman corporation describes a patented method for the

	
  
Figure 51 Comparision of nicotianamine from whole soybean precipitate, soy flour precipitate,
and nicotianamine standard.
extraction of nicotianamine from soy flour which was followed, with some steps adjusted as
needed (Figure 52).64
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Eighty grams of Hodgson’s Mill soy flour was used. The first step involved adding one
liter of water to this dry material and adjusting the pH to 9 using 6 M NaOH. A stir plate was
used and this mixture was stirred for approximately two hours. This material was then filtered
through a stainless steel sieve. The pH was then adjusted to 4.5 and the material was centrifuged
at 4000 RPM for 30 minutes in order to precipitate the proteins from the solution.
Thirty grams of activated carbon was then added to this solution and it was stirred using a
magnetic plate and stir bar for approximately four hours. Afterward, filter aid was added and the
solution was stirred for approximately one more hour. This material was then filtered and
lyophilized yielding approximately 17 grams.
approximately 0.3% nicotianamine (Figure 53).
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LC-MS quantification showed a yield of

Figure 52 Nicotianamine isolation scheme

	
  

58	
  

	
  

Figure 53 Yield of nicotianamine from soy flour

	
  

	
  
Figure 54 Yield of nicotianamine from soy flour after multiple purification steps
This freeze dried material was dissolved in 50 mL of H2O. Next, this solution is made
into an 80% solution of ethanol on a w/w basis by adding 130 mL of ethanol. This mixture was
then centrifuged for 30 minutes at 4 °C at 4000 RPM. The supernatant was discarded and the
pellet is kept. After lyophilization, this material contained 1.0% nicotianamine (Figure 54).
In order to test this material and be sure that nicotianamine was the ion signal that
was being analyzed, a co-injection with the nicotianamine standard was performed (Figure 55).
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Figure 55 Co-injection of nicotianamine and extract

	
  

This scheme provides a relatively straight-forward way to purify a natural metalchelating agent from a cheap, readily available source. Nicotianamine could replace EDTA to
prevent metal-catalyzed spoilage and still enable food products to be labeled as “all-natural.”
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CHAPTER FOUR:
HCV REVIEW
The goal of HCV therapy is a sustained virologic response (SVR), which is achieved
when HCV RNA cannot be detected in serum 24 weeks after therapy has ended. The currently
prescribed therapy against HCV is a combination of ribavirin and either peginterferon alfa-2a or
peginterferon alfa-2b.

Less than half of patients infected with HCV genotype 1, the most

prevalent genotype in patients in the United States, achieve an SVR with standard
ribavirin/interferon combination therapy.94 The FDA recently approved two protease inhibitors,
telaprevir and boceprevir, for the treatment of genotype 1 HCV. Telaprevir has been shown to
significantly improve the SVR in patients when administered along with the HCV standard
combination therapy of ribavirin and peginterferon.95 However, the chance that patients will
discontinue therapy due to adverse side effects is also increased.95 There have been significant
differences in response to therapy based on genotype. For example, in one recent clinical study
patients infected with genotype 1 showed a decrease in viral load of 4.4 log10 IU/mL after two
weeks of monotherapy of telaprevir; patients with genotype 4 HCV only showed a decrease of
0.9 log10 IU/mL.96 Differences in efficacy have also been noted in NS5B non-nucleoside
inhibitors as well. In another recent clinical study, VCH-259, a DAA that binds to the thumb 2
site of the NS5B RdRp, was administered for 10 days to an HCV genotype 1 patient after which
HCV RNA had decreased by a mean maximal of 2.5 log10 IU/mL. The same conditions were
tested for a patient infected with genotype 6 and no viral decline was reported.97
The two most recent drugs approved for HCV treatment are simeprevir (Olysio®) and
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sofosbuvir (Solvaldi®).98-99 Simeprevir is an NS3/4 protease inhibitor that has been shown to
significantly increase SVR rates in patients with genotype 1 after 24 weeks when given in
combination with interferon and ribavirin when compared to interferon and ribavirin alone or
placebo.100 Sofosbuvir is a RNA polymerase inhibitor that has been shown to significantly
increase SVR rates in both genotype 1 and 4 patients when given with ribavirin and interferon.101
Interestingly, sofosbuvir has also shown efficacy in genotype 1 patients in combination with
ribavirin but without interferon.102 This represents a major step forward as interferon side effects
often stop patients from continuing a full regiment of HCV. However, the cost of these new
drugs can be a major issue for certain segments of the population, especially for people in
developing countries. The giant steps forward in knowledge of the HCV life cycle played a huge
role in

the development of these new agents and have also allowed for screening of natural

product leads for HCV.
HCV is an enveloped virus containing a lipid bilayer that surrounds the nucleocapsid. E1
and E2 are two structural glycoproteins that are anchored in the lipid bilayer and participate in
host cell receptor binding. Recent studies have shown that E1 and E2 are stabilized by covalent
disulfide bridges once exported to the bilayer and that glycosylation of certain sites are vital for
both infectivity and evading the host immune response.103 There have been numerous studies
attempting to elucidate the mechanism for HCV binding. The low-density lipoprotein receptor
(LDL-R),104 the cell receptor CD81,105 the human scavenger receptor class B type I (Sr-BI),106
and claudin-1,107 a protein involved in tight-junction cell-to-cell adhesion, have all been studied
to understand their roles in HCV entry.
The HCV genome is composed of a ~9600 bp length, positive sense strand mRNA that is
translated by a negative strand intermediate. The genome includes: a 5´ non-coding region
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(NCR) that contains the internal ribosome entry site (IRES), the ORF that encodes the single
polyprotein, and the 3´ NCR.108 The IRES directs translation of HCV mRNA by a mechanism
that is distinct from host cell eukaryotic translation.109 The HCV ORF encodes, starting from the
5´ end: the core nucleocapsid; the E1 and E2 envelope proteins; the p7 ion channel; the NS2-3
protease; the NS3 serine protease and RNA helicase; the NS4A polypeptide; the NS4B and
NS5A proteins; and the NS5B RNA-dependent RNA polymerase (RdRp).110 The developing
polyprotein is processed by both the host endoplasmic reticulum signal peptidase and the NS2-3
protease and the NS3-4A serine protease.110 The polyprotein product contains a signal sequence
between the core nucleocapsid encoding region and the E1 envelope coding region which directs
it to the host endoplasmic reticulum (ER) membrane.111 After the E1 region has been
translocated into the endoplasmic reticulum, the core protein is cleaved and processed and
subsequently associates with lipid droplets.111 The E1 and E2 proteins are glycosylated by the
host ER and ER chaperones are involved in proper E1 and E2 folding.112
The p7 ion channel has been shown to be vital for infectivity using mutational studies,
and also for viron assembly by interacting with the NS2 and E1 proteins.113 Another possible role
for this protein may be to regulate pH in intracellular compartments of the host cell.114
HCV relies on two proteases; the first, NS2-3, is responsible for a single cleavage at the
NS2/NS3 junction. The next protease, the NS3-4A serine protease and RNA helicase complex,
is responsible for cleavage between the NS3/4A cofactor (self-cleavage), and between the
NS4A/4B, NS4B/5A, and NS5A/5B proteins.73,115
The NS4B protein is involved in forming the membranous network where HCV
replication takes place,116 while the NS5A proteins has proven to contain RNA binding
properties,117 be involved in alpha-interferon resistance,118 and possibly contribute to liver
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steatosis.119 The final protein in the ORF sequence is the NS5B RNA-dependent RNA
polymerase (RdRp), which is responsible for synthesizing a negative-strand template from the
original positive oriented strand to facilitate positive strand replication, and is used in HCV
classification.
Less is known about HCV packaging and assembly, but there has been a number of
studies published in this area in recent years.120 One study has suggested that HCV co-opts the
cellular production and release of very-low-density-lipoproteins (VLDL), which, through a kind
of mimicry, allows HCV to persist.121 One particular protein involved in VLDL production that
seems to be important in HCV production is apolipoprotein E.122 Other proteins that have been
implicated in HCV production are heat shock cognate protein 70,123 annexin A2,124 and
diacylglycerol acyltransferase-1.125
Plant Derived HCV Natural Product Inhibitors
The HCV NS3-4A protease as emerged has a primary target for DAA agents. Four new
iridoid glucosides were recently isolated from Anarrhinum orientale, a plant in the order
Lamiales. Iridoids are monoterpene glycosides which are widely found in Lamiales.126 One of
these newly isolated irdoids (1), had an IC50 value of 100 µM against the NS3 protease (Figure
42). This compound also showed selectivity for the HCV NS3-4A protease as the IC50 values for
the human trypsine protease were above 200 µM.126
A recent study that screened more than 150 plants with reported medicinal properties for
anti-HCV activity showed activity in the methanol extract of the root bark of species in the
Morus genus.127 Bioassay-guided fractionation yielded five known 2-arylbenzofuran derivatives
from the original extract. Four of these compounds mulberroside C, moracin P, moracin O, and
moracin M, showed inhibitory activity against HCV, with moracin P and moracin O showing
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potent activity. Moracin P (2) had an IC50 value of 35.6 µM and moracin O (3) an IC50 of 80.8
µM in a Huh-7 cell replicon assay. These compounds were further tested for specific activity
against NS3-4A helicase activity. Moracin O had an IC50 of 42.9 µM, while moracin P showed
an IC50 of 27.0 µM.127

Figure 56 Plant-derived inhibitors of HCV

	
  

Another recent study screened a natural product compound library derived from
American and African flora for anti-HVC activity and found HCV inhibition in extracts of the
aerial parts of Parthenium hispitum.128 Bioassay guided fractionation yielded a series of
pseudoguaianolides, a group of sesquiterpene lactones, three of which (4-6) yielded primary
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inhibition of HCV above 90% at a 2 µM concentration.128 Shikonin (7) is a naphthoquinone
derivative that has been isolated from Arnebia euchroma in past studies and shown activity
against HIV-1 in vitro and has antiangiogenic and antitumorigenic properties.129 It was recently
tested against HCV and had an EC50 value of 0.025 µg/mL.130 Further cytotoxicity test proved
the selectivity index of shikonin to be relatively high at 43.56 (CC50/EC50).130
Diosgenin (8) is a steroidal sapogenin that has been isolated from tubers in the genus
Dioscorea. A recent study that tested diosgenin against HCV using an enhanced green
fluorescent protein reporter based assay demonstrated an EC50 value of 3.8 µM.131 Further
experiments using Western blot analysis showed that diosgenin had an additive effect when
administered with interferon-alpha on inhibition of the HCV NS3-4A protease.131
Another large scale screening procedure which utilized plants used in traditional
medicine in Sudan yielded two benzoquinones that showed significant activity against the HCV
protease.132 These two compounds, embelin (9) and 5-O-methylembelin (10) were isolated from
the fruit of an Embelia schimperi species. Embelin gave an IC50 of 21 µM, while 5-Omethylembelin gave a reported IC50 of 46 µM when tested for inhibitory activity against the
HCV NS3-4A protease.132
Another study, this time involving screening plants from Peru, yielded two new
polyphenolic compounds that showed significant activity against the HCV NS3-4A protease.133
Both compounds were isolated from the methanol extract of Stylogone cauliflora. SCH 644342
(11) showed an IC50 value of 0.8 µM, while SCH 644343 (12) gave an IC50 value of 0.3 µM.133
Microbial Derived HCV Inhibitors
In 1996, a new quinone compound, SCH 68631 (13), was isolated from the fermentation
broth of a soil microorganism isolated from a forested area in Nepal (Figure 43).134 The original
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material was extracted with ethyl acetate and a biphasic solvent partitioning system was used for
further purification. The active fraction was then subjected to HPLC. SCH 68631 gave an IC
value of 2.5 µg/mL when tested against the NS3-4A protease.134
Another novel compound from a soil microorganism was isolated in 1999 that showed
high anti-HCV activity. Penicillium griseofulvum is a fungus that was isolated from a desert
ecosystem in Arizona.135 The fermentation broth of this organism was extracted with ethyl
acetate and then purified using liquid partitioning and HPLC, yielding SCH 351633 (14), a novel
bicyclic hemiketal lactone. This new compound gave an IC50 value of 3.8 µg/mL when tested
against the HCV NS3-4A protease.135
Marine Derived HCV Natural Products Inhibitors
Manoalide (15) is sesterpenoid first isolated from the sponge Luffariella variabilis.136 It
was recently screened for antiviral activity and was shown to inhibit the ATPase, RNA binding,
and helicase activities of the HCV NS3 protease.136

Figure 57 Microbial-derived HCV inhibitors

	
  

The discorhabdins are a group of pyrroloiminoquinone alkaloids derived from sponge
species in the genus Latrunculia. Two compounds in this class have shown potent activity in an
HCV replicon assay.137 Discorhabdin A (16) had an EC50 value above 90% at concentrations less
than 10 µM.137
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Figure 58 Marine-derived inhibitors of HCV
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CHAPTER FIVE:
CONCLUSIONS
Platanus occidentalis and Bacillus amyloliquefaciens
Endophytes are bacterial and fungal symbionts that reside in plant tissue without causing
disease and numerous studies have proven these microbes are engaged in a symbiotic
relationship with the host plant. The functions that the endophytes provide for the host are
varied and studies on the ecology of endophytes are still ongoing, but the nature of these
relationships has been elucidated in many host plant species and is of great importance to many
important agricultural crops. For example, endophytes that reside in the leaves of Theobroma
cacao enhance host defenses against the pathogen Phytophthora palmivora.138 In rice (Oryzae
sativa), endopytes regulate resources to optimize root growth while root hairs are being
established.139 Another recent study showed that in wheat (Triticum spp.), endophytes help host
plants to adapt to heat and drought conditions.140
Bacillus spp. of bacteria are known to produce a diverse set of secondary metabolites
including lantibiotics, lipopeptides, polyketides, and others.17 Rapamycin is a polyketide
molecule which is of major interest due to wide-ranging activity including antitumor42 and
immunosuppressant activities43 and research into the efficacy of rapamycin against many human
ailments is ongoing. Here we have increased the knowledge base in regards to this important
molecule in a number of ways. We have shown that another species other than Streptomyces
hygroscopicus produces this important molecule. The fact that a Bacillus species produces
rapamycin could have wide ranging effects in the pharmaceutical industry as Bacillus species are
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historically very amenable to genetic engineering. Typically, drug molecules that are produced
by microbial species have been modified and engineered to increase production of the molecule
of interest. Actinomycetes are known to be much more difficult to grow than Bacillus spp. and
thus this strain of B. amyloliquefaciens could be a viable alternative to develop. Genetic
engineering methods for increasing production would need to be developed in order to compete
with current rapamycin producers.
Another finding that is important to rapamycin research is the possible discovery of a
rapamycin analogue. One of the many reasons the original report of rapamycin was such an
important discovery was not in regards to the molecule itself, but was due to the fact that this led
to the discovery of Target of Rapamycin (TOR) protein kinases.44 TOR is important in both
primary and clinical biology; in primary biology, it is the main controller of cellular growth and
aging in eukaryotic cells that coordinates environmental signals with the appropriate response.141
As mentioned previously, TOR proteins are part of at least two protein complexes, TORC
(Target of Rapamycin Complex) 1 and TORC2. Interestingly, rapamycin only binds to TOR that
is part of TORC1 and thus analogues would be of high interest to test binding differences in
these different complexes. TORC1 signaling is thought to be overactive in a majority of cancers,
so any differences in binding or subsequent activity in TOR as part of TORC1 would be of
substantial interest as well.45 Although there have been substantial leaps in knowledge with
regards to TORC1 and TORC2 signaling and activation, this is still an active area of research.45
If the putative rapamycin analogue binds to either complex in a distinct manner, this could assist
biochemical investigations of these pathways.
Another way that this work has contributed to the study of secondary metabolites is by
demonstrating the need for future investigations into silent gene expression from microbial
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species. Natural products are responsible for greater than 70% of antibiotics and 55% of
antiviral medications.142 Most of these were discovered in the 1940s and 1950s in what is now
heralded as the Golden Age of Antibiotics.143 A number of strategies have been developed in
order to try and elicit or activate silent gene clusters that are not active under normal laboratory
conditions.143 Here, we show a Bacillus species from the very common P. occidentalis has the
ability to produce rapamycin, a secondary metabolite that was first discovered on Easter Island,
2000 miles of the coast of Chile. This shows how a deeper understanding of silent gene
expression, and also the chemical ecology underlying the endophyte-host plant relationship, will
be important for future drug discovery efforts.
Perhaps the most intriguing part of this work was the possible biotransformation of the
rapamycin metabolite by the host plant. Rapamycin has been shown to be detrimental to plant
growth, yet also contains strong antifungal activity that the host plant could utilize to ward off
pests. It will be of great interest to determine if the putative analogue is also detrimental to plant
growth and how overall binding to rapamycin sensitive proteins is affected by structure changes.
Certain Bacillus spp. are known to be plant growth promoters.144 Owing to the wide ranging
effects of rapamycin on TOR there are many different hypotheses that could be developed to
explain rapamycin production by Bacillus spp. and the subsequent putative biotransformation
product.
The MALDI-IMS challenge experiment demonstrates an important, innovative way to try
and understand plant-endophyte relationships and host regulation of endophyte-produced
secondary metabolites. B. thuringiensis (Bt) has been used in the past in agriculture and other
applications due to its ability to produce insecticidal proteins.15 Efforts have been underway to
improve production of these proteins and to increase the ability of Bt to act as a biopesticide
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using genetic manipulation.145 As mentioned previously, Bacillus spp. produce the antifungal
lipopeptide iturins and these molecules have proven activity against a number of agricultural
pathogens including those associated with powdery mildew and root rot.29 There is a proven link
between the level of iturin production from endophytic Bacillus spp. and the ability of Triticum
spp. to fight the fungal infection Fusarium head blight.146 An understanding of how the plant
hosts regulate the production of this lipopeptide could be an important component in developing
methods to increase the output of iturin production in the field. Understanding host regulation of
endophyte-produced natural products is also an important facet of natural product drug research.
Nicotianamine
There has been a general trend in the market place towards all-natural or organic foods.65
Food industries that attempt to provide products which are packaged as “all-natural” can
encounter significant problems when attempting to prevent long term food spoilage.
Ethylenediaminetetraacetic acid (EDTA) is a common metal chelator that is added to food
products to prevent spoilage. As a synthetic product, addition of this agent disables food
companies of the ability to label their products as all-natural or organic, even if strict protocols to
growing all natural or organic foods have been followed.
Nicotianamine is a natural metal chelating agent which presents a viable alternative to
EDTA in the food industry. Here, we show that nicotianamine can be obtained from readily
available soy flour. This soy flour was easier to manage and contained a higher yield of
nicotianamine when compared to a trial that used whole soybeans. In addition, although
patented methods contained a variety of methods for nicotianamine purification, here we report
that ethanol precipitation after activated carbon treatment was a vastly improved strategy due to
lowering the amount of ethanol needed for precipitation. This is particularly important to food
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conglomerates which might produce soy products in certain areas of their overall business plan
and could use resources that are already available to produce a natural replacement for EDTA.
The Hepatitis C Virus
The hepatitis C virus (HCV) is responsible for chronic hepatitis C, which can lead to
cirrhosis of the liver and hepatocellular carcinoma. This is a major health concern as an
estimated 130-170 million people worldwide are infected with HCV.68 More than 350,000
people die from chronic HCV related diseases annually every year, with an estimated 3-4 million
new individuals infected each year.68 Co-infection with HIV is also a major concern as this
increases the chances of liver disease three fold.69
Here, we review natural products that have shown in vitro HCV activity. The latest
findings on HCV proteins and the HCV life cycle are reviewed as well. The discovery of the
HCV virus and the elucidation of its life cycle has happened in relatively recent times.
Difficulties in culturing this virus was the major hurdle in discovering the etiologic agent of
hepatitis C. These difficulties have largely been overcome and permitted novel screening
techniques of natural products against different targets of HCV. As demonstrated in this review,
natural products are an important source of active metabolites against new targets for HCV
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EXPERIMENTAL SECTION
Glycerol Stocks: There were a total of six glycerol stocks supplied by Dr. Mohammed
Ibrahim. Glycerol stock labeled Xf1 was used to make multiple other glycerol stocks by plating
5 µL of Xf1 glycerol stock on solid agar and allowing it to grow at 36 °C for 48 hours. Colonies
were then streaked using sterile technique into 10:5 milliliters of liquid CS20 media. Tubes were
shaken for approximately 48 hours at 36 °C at 160 RPM in a New Brunswick Series 25
Incubator Shaker. These cultures were used for creating a total of 30 glycerol stocks by
removing 600 µL of media and adding to Eppendorf tubes and mixing with 400 µL of 60%
glycerol stock solution. Glycerol stocks were placed in Thermo Fisher Scientific -86 °C freezer.
Endophyte isolation: P. occidentalis stem material was surface sterilized using 80%
EtOH for 4 minutes under bio-hood under sterile conditions. Bio-hood was UV irradiated prior
to endophyte isolation. Outer bark was peeled off using knife and forceps that had been soaked
in 80% EtOH for ten minutes and flamed. Inner layer of bark tissue and exposed inner stem
were placed directly on malt agar. Agar plates were sealed with Parafilm® in bio-hood. Plates
were incubated at 36 °C for 48 hours. Bacterial growth emerged directly from exposed stem
material. Bacterial colonies growing directly from exposed stem were sub-cultured under sterile
conditions. Sub-cultured plates were used to make (10) 5 mL liquid cultures using sterile
conditions. 5 mL liquid cultures were shaken at 160 RPM and 36 °C for 24 hours. Glycerol
stocks were made by pipetting 600 µL of liquid culture and 400 µL of 80% glycerol into
Eppendorf tubes. Tubes were placed in -80 °C freezer for storage.
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HP-20 extractions: The first step in testing secondary metabolite production was to
plate 5 µL of glycerol stock on solid agar CS20 plates. After 48 hours of growth at 36 °C,
cultures were streaked from plates under sterile conditions into 2:5 mL tubes of liquid CS20
media. In the first extraction process, 2:100mL cultures were inoculated using the 5 mL starter
cultures. Cultures were removed and sonicated in a Branson 8510 Ultrasonic Cleaner for one
hour. Afterwards, cultures were centrifuged in an ThermoIEC Centra CL3R centrifuge for 10
minutes at 4000 RPM. The cell pellet was subsequently discarded. HP-20 Diaion resin beads
(10 g) were added to each of the 100 mL flasks and flasks were put back in the shaker for 12
hours. HP-20 beads were filtered using a Buchner funnel and Whatman No. 1 filter paper. The
liquid was subsequently discarded and 100 mL of EtOH was passed over beads followed by 100
mL of EtOAc. Note that for all subsequent extractions the amount of liquid used for each
solvent was equal to the original amount of culture that was fermented. Each extract was
evaporated in a Büchi R-200 Rotavapor in conjunction with a Büchi B-490 heating bath. In
order to complete evaporation, samples were placed in a Savant Speed-Vac SC210A in
conjunction with an FTS 8L vapor trap.
NPNCR Bioassays: The general procedure was as follows. Crude extracts were tested in
a primary screen which used a concentration of 50 µg/mL and tests extracts in duplicate. Percent
inhibitions were calculated relative to positive and negative controls. A total of 5 pathogenic
bacteria and 5 pathogenic fungi were used for screening. These include: C. albicans, C.
glabrata, C. krusei, A. fumigatus, and C. neoformans in the fungal category, and: Staph. aureus,
MRSA, E. coli, P. aeruginosa, and M. intracellulare in the bacterial category. The amount of
crude material that was submitted was in the range of 10-90 mg of material. This work was
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completed under a grant by NIH, NIAID, Division of AIDS, grant number: AI 27094.
Screenings were performed by Ms. Marsha A. Wright and reported by Dr. Melissa Jacob.
LC-MS. Samples were prepared by dissolving 1 mg of material into 1 mL of MeOH.
Samples were run using a 20 µL injection volume. Method used ran a gradient of 80% H2O/20%
MeOH to 100% MeOH over a period of 24 minutes. Each solvent had 0.05% formic acid added
prior to being used a with binary pump.
Challenge Experiment P. occidentalis wood was processed into sawdust. Wood was
lyophilized using a Labconco ® FreeZone 2.5 L Freeze Dry System. This material was then
extracted with hexanes, chloroform, and methanol using a total of three extractions for each
solvent. The material was then covered with solvent and placed in a a Branson 8510 Ultrasonic
Cleaner for one hour, filtered through a a Buchner funnel, and the solvent evaporated a Büchi
rotary evaporator R-200 used in conjunction with a Büchi B-490 heating bath. The same
procedure was repeated a second time using the same solvent and the same material. For the
third extraction, the same procedure was followed, with the exception that after sonication the
material was left in solvent overnight for approximately 24 hours before extraction using the
Buchner funnel. Following rotary evaporation, all extracts were placed in a Savant Speed-Vac
SC210A in conjunction with an FTS 8L vapor trap to remove solvent. The glycerol stock (5µL)
was placed in the center of 5 different CS20 solid agar plates. These were then surrounded by
the three different P. occidentalis extracts on three different sides of the colony. These extracts
were re-dissolved in the original solvent with using a pre-calculated volume so that 10 µL of
liquid extract would equal half a milligram of extract. These were placed in such a way so that
over the 5 day period, the bacterial colony would expand to eventually come into contact with
the extracts. It was important to have the extracts placed sufficiently far away which would
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allow for imaging the colony before it reached the extracts but also not too far away which
would prevent the colony reaching the extracts in five days.
Genome Assembly Bacillus sp. was sequenced by collaborators at University of
Maryland and submitted as two fastq files (R1 and R2). Geneious software was used for
assembly. Mapping assembly was used with NCBI reference sequence Bacillus subtilis
NC_000964.3. Sensitivity settings were set to medium.
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